194 related articles for article (PubMed ID: 18670745)
1. Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients.
Degrate L; Nobili C; Franciosi C; Caprotti R; Brivio F; Romano F; Leone BE; Trezzi R; Uggeri F
Langenbecks Arch Surg; 2009 Jan; 394(1):115-21. PubMed ID: 18670745
[TBL] [Abstract][Full Text] [Related]
2. Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: a randomized study.
Uggeri F; Caprotti R; De Grate L; Crippa S; Nobili C; Penati C; Romano F
Hepatogastroenterology; 2009; 56(91-92):861-5. PubMed ID: 19621718
[TBL] [Abstract][Full Text] [Related]
3. Prolonged survival of a patient affected by pancreatic adenocarcinoma with massive lymphocyte and dendritic cell infiltration after interleukin-2 immunotherapy. Report of a case.
Nobili C; Degrate L; Caprotti R; Franciosi C; Leone BE; Trezzi R; Romano F; Uggeri F; Uggeri F
Tumori; 2008; 94(3):426-30. PubMed ID: 18705415
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
5. Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
Brooks J; Fleischmann-Mundt B; Woller N; Niemann J; Ribback S; Peters K; Demir IE; Armbrecht N; Ceyhan GO; Manns MP; Wirth TC; Kubicka S; Bernhardt G; Smyth MJ; Calvisi DF; Gürlevik E; Kühnel F
Cancer Res; 2018 Jan; 78(2):475-488. PubMed ID: 29180478
[TBL] [Abstract][Full Text] [Related]
6. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.
Bernstein ZP; Porter MM; Gould M; Lipman B; Bluman EM; Stewart CC; Hewitt RG; Fyfe G; Poiesz B; Caligiuri MA
Blood; 1995 Nov; 86(9):3287-94. PubMed ID: 7579429
[TBL] [Abstract][Full Text] [Related]
7. Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
Bovo G; Brivio F; Brenna A; Fumagalli L; Perego P; Brivio O; Uggeri F; Lavorato F; Bratina G
Pathologica; 1995 Apr; 87(2):135-8. PubMed ID: 8532404
[TBL] [Abstract][Full Text] [Related]
8. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
9. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
11. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
12. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
13. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
[TBL] [Abstract][Full Text] [Related]
14. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.
Fabian I; Kravtsov V; Elis A; Gurevitch O; Ackerstein A; Slavin S; Nagler A
Leukemia; 1994 Aug; 8(8):1379-84. PubMed ID: 8057677
[TBL] [Abstract][Full Text] [Related]
15. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy.
Cools KS; Sanoff HK; Kim HJ; Yeh JJ; Stitzenberg KB
J Surg Oncol; 2018 Sep; 118(3):455-462. PubMed ID: 30114330
[TBL] [Abstract][Full Text] [Related]
16. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Group of Pancreatobiliary Surgery in Japan.
Satoi S; Murakami Y; Motoi F; Sho M; Matsumoto I; Uemura K; Kawai M; Kurata M; Yanagimoto H; Yamamoto T; Mizuma M; Unno M; Kinoshita S; Akahori T; Shinzeki M; Fukumoto T; Hashimoto Y; Hirono S; Yamaue H; Honda G; Kwon M
Pancreas; 2016 Aug; 45(7):1003-9. PubMed ID: 26692442
[TBL] [Abstract][Full Text] [Related]
17. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy.
Suto H; Okano K; Oshima M; Ando Y; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Suzuki Y
BMC Surg; 2019 Dec; 19(1):186. PubMed ID: 31796066
[TBL] [Abstract][Full Text] [Related]
18. Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma.
Lee HS; Leem G; Kang H; Jo JH; Chung MJ; Jang SJ; Yoon DH; Park JY; Park SW; Song SY; Bang S
J Gastroenterol Hepatol; 2021 Feb; 36(2):516-522. PubMed ID: 32969514
[TBL] [Abstract][Full Text] [Related]
19. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results.
Angelini C; Bovo G; Muselli P; Mussi C; Crippa S; Caprotti R; Uggeri F
Hepatogastroenterology; 2006; 53(67):141-4. PubMed ID: 16506394
[TBL] [Abstract][Full Text] [Related]
20. Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients.
Nicolini A; Mancini PA; Ferrari P; Anselmi L; Sagripanti A; Carpi A
Biomed Pharmacother; 1996; 50(8):344-9. PubMed ID: 8952853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
